Latest News

Print Page Print Page | E-mail Page E-mail Page | RSS Feeds RSS Feeds

Keyword Search
 
2014 | 2013 | 2012 | 2011 | 2010
10/22/14AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results
Results indicate Zalviso controlled moderate-to-severe acute pain following abdominal surgery better than placebo, with similar side effect profile REDWOOD CITY, Calif., Oct. 22, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that results from the  IAP310 study have been published in Regional Anesthesia and Pain Medicine (RAPM), a peer-reviewed journal with broad, multidisciplinary readership. IAP310 was a randomized, placebo-controlled, Phase 3 trial evaluat... 
Printer Friendly Version
10/16/14AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary Platform Technologies
Patent estate includes thirteen issued U.S. patents, thirty patents worldwide REDWOOD CITY, Calif., Oct. 16, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 30 issued patents worldwide. These issued patents cover AcelRx's sufentanil Nanotab®, medi... 
Printer Friendly Version
10/10/14AcelRx Pharmaceuticals Announces Multiple Sublingual Sufentanil Data Presentations At The American Society Of Anesthesiologists Meeting
Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response REDWOOD CITY, Calif., Oct. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the upcoming American Society of Anesthesiologists (ASA 2014) meeting October 11th to October 15th, 2014 at the Ernest N. Morial Convention Center in New Orleans, LA.  The annual ASA meeting ... 
Printer Friendly Version
10/06/14Sufentanil sublingual tablet system study results to be presented at the International Association for the Study of Pain Meeting
REDWOOD CITY, Calif., Oct. 6, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that a new data analysis from previously reported phase 3 studies evaluating the sufentanil sublingual  tablet system (SSTS) for the treatment of moderate-to-severe acute pain will be presented at the International Association for... 
Printer Friendly Version
09/26/14AcelRx Pharmaceuticals Provides Regulatory Update on Zalviso™
REDWOOD CITY, Calif., Sept. 26, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso™ (sufentanil sublingual tablet system).  The Company recently held a teleconference with representatives from the Food and Drug A... 
Printer Friendly Version
09/10/14AcelRx Announces Publication of Manuscript Analyzing Cost of Intravenous Patient-Controlled Analgesia with Opioids
REDWOOD CITY, Calif., Sept. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of a pharmacoeconomic analysis of the cost of intravenous patient-controlled analgesia with opioids based on current literature and data from over 500 U.S. hospitals.  The manuscript entitled 'Cost of Opioid ... 
Printer Friendly Version
09/04/14AcelRx Announces Publication of Sufentanil Sublingual Tablet System vs. Intravenous Patient-Controlled Analgesia with Morphine for Postoperative Pain Study Results
REDWOOD CITY, Calif., Sept. 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of the results of a study to evaluate patient satisfaction with a novel sublingual sufentanil patient-controlled analgesia (PCA) system compared to the standard intravenous PCA for the management of acute postoper... 
Printer Friendly Version
08/27/14AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
REDWOOD CITY, Calif., Aug. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at the FBR Healthcare One on One Conference and presenting at the Morgan Stanley Global Healthcare Conference.  Details of the two events are as follows: FBR Healthcare One on One C... 
Printer Friendly Version
08/11/14AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
REDWOOD CITY, Calif., Aug. 11, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2014.  On July 25, 2014, AcelRx announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's new drug ... 
Printer Friendly Version
08/08/14AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at three upcoming investor events. Details of the three events are as follows: Canaccord 34th Annual Growth Conference Date: Wednesday August 13th Location: Boston, MA Presentati... 
Printer Friendly Version
08/07/14AcelRx Pharmaceuticals to Hold Second Quarter Financial Results Conference Call and Webcast on Monday, August 11th, 2014.
REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second quarter 2014 financial results after market close on Monday, August 11th, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on ... 
Printer Friendly Version
07/25/14AcelRx Pharmaceuticals Receives Complete Response Letter from FDA for New Drug Application for Zalviso™
REDWOOD CITY, Calif., July 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso™ (sufentanil sublingual tablet system).  The Company is currently reviewing the... 
Printer Friendly Version
07/24/14AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso
REDWOOD CITY, Calif., July 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today confirmed the PDUFA date for Zalviso remains July 27, 2014.  The company recently learned that a rumor circulated online stating the Food and Drug Administration (FDA) had approved Zalviso.  As of July 24, 2014 there has been no notific... 
Printer Friendly Version
07/07/14AcelRx and Grunenthal Announce Submission of European Marketing Authorization Application for ZALVISO™
- MAA submission triggers $5 million milestone payment to AcelRx REDWOOD CITY, Calif. and AACHEN, Germany, July 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO™ for the management of moderate to severe acute pain in adult patients in a medically supervised environment.  ZALVISOTM is a drug-device combination product ... 
Printer Friendly Version
06/19/14AcelRx Pharmaceuticals to Present at the JMP Securities Healthcare Conference
REDWOOD CITY, Calif., June 19, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will present a corporate overview on June 25th.  Presentation details are as follows: JMP Securities Healthcare Conference Date: Wednesday, June 25th Location: The Westin New York Grand Central, New Yo... 
Printer Friendly Version
06/03/14Results of Cost Analysis Study Presented at ISPOR Meeting Identify Intravenous Patient-Controlled Analgesia (IV PCA) Costs of $200 to $240 for Two Days of Post-Surgical Pain Management
Additionally, Results of Independent Survey Show IV PCA a Burden for Postoperative Care Nurses Both Cost Analysis and Survey Findings Underscore Need for Cost-Effective, Patient and Nurse Friendly In-Hospital Pain Management Innovations REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, tod... 
Printer Friendly Version
06/02/14AcelRx Pharmaceuticals Announces The Departure Of David Chung
REDWOOD CITY, Calif., June 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David Chung has resigned as Chief Commercial Officer in order to assume the role of Chief Executive Officer of a medical device company.  Richard King, the Company's President and Chief Executive Officer, will assume the duti... 
Printer Friendly Version
05/29/14AcelRx Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 29, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will present a corporate overview on June 3rd.  Presentation details are as follows: Jefferies Global Healthcare Conference Date: June 3, 2014 Location: Grand Hyatt New York Presentation Time: 1:30 pm ... 
Printer Friendly Version
05/19/14AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
REDWOOD CITY, Calif., May 19, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview on May 20th.  Presentation details are as follows: UBS Global Healthcare Conference Date: Tuesday, May 20, 2014 Location: Sheraton New York Hotel Prese... 
Printer Friendly Version
05/08/14AcelRx Pharmaceuticals Reports First Quarter 2014 Financial Results
REDWOOD CITY, Calif., May 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three months ended March 31, 2014. "In the first quarter of the year, we have focused on preparation for commercialization of Zalviso both in the U.S. and Europe.  This includes working with the FDA on t... 
Printer Friendly Version
05/02/14AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Thursday, May 8, 2014
REDWOOD CITY, Calif., May 2, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2014 financial results after market close on Thursday, May 8, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 8,... 
Printer Friendly Version
05/01/14AcelRx Pharmaceuticals Announces Zalviso™ and ARX-04 Data Presentations at the American Pain Society 33rd Annual Scientific Meeting
REDWOOD CITY, Calif., May 1, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that multiple Zalviso and ARX-04 data presentations will be made at the American Pain Society's (APS) 33rd Annual Scientific Meeting held on April 30 to May 3 in Tampa, Florida. The APS Annual Scientific Meeting is the premier pain... 
Printer Friendly Version
04/04/14AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
REDWOOD CITY, Calif., April 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9th. Presentation details are as follows: 13th Annual Needham Healthcare Conference   Date:  Wednesday, April 9, 2014  ... 
Printer Friendly Version
03/25/14AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
REDWOOD CITY, Calif., March 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO).  Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most... 
Printer Friendly Version
03/07/14AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
REDWOOD CITY, Calif., March 7, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference: 26th Annual Roth Conference Date:  Tuesday, March 11, 2014 Location:  The Ritz Carlton, Laguna Niguel, CA Presentation Time:  1... 
Printer Friendly Version
03/03/14AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
REDWOOD CITY, Calif., March 3, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. "AcelRx made strong progress in 2013 with the successful completion of the Zalviso™ (sufentanil sublingual NanoTab system) Phase 3 program, the filing a... 
Printer Friendly Version
02/24/14AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
REDWOOD CITY, Calif., Feb. 24, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014.  AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on Ma... 
Printer Friendly Version
02/05/14AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
REDWOOD CITY, Calif., Feb. 5, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences.  Details of the three events are as follows: BIO CEO & Investor Conference Date:  Tuesday, February 11, 2014 ... 
Printer Friendly Version

AcelRX

CONTACT